Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses the molecular mechanisms of androgenetic alopecia and evaluates current and potential treatments, highlighting the limitations of minoxidil and finasteride and exploring newer approaches like growth factors and cytokines, topical 5-alpha-reductase inhibitors, and platelet-rich plasma injections as more effective and safer alternatives.

This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

This paper discusses mechanisms by which various chemicals disrupt male sexual differentiation, concluding that mixture risk assessments should include a broader set of compounds beyond phthalates to address cumulative reproductive health risks.

This study suggests that thermal imaging may aid in diagnosing cellulitis, potentially improving patient care, although its applicability to certain cases requires further investigation.

A substance called prostaglandin D2 is linked to stopping hair growth in men with common baldness.

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

This study found that topical rebamipide, originally a gastric ulcer medication, can activate hair follicle stem cells and promote hair regeneration by modulating dermal adipocyte metabolism, with potential targeting of the prostaglandin E receptor EP4.

This review discusses genetic and pharmacogenetic insights, along with RNA interference technologies, for developing personalized therapies for androgenetic alopecia, yet presents no new clinical results.

This study found that 15-dPGJ2 promotes apoptosis in human follicular keratinocytes, suggesting its potential role in developing hair loss prevention treatments through DP2 antagonism.

This report describes a case where travoprost treatment for open-angle glaucoma was associated with periocular hypertrichosis, hyperpigmentation, and eyelash growth, which gradually improved after discontinuation.

This review synthesizes knowledge on Prostaglandin E2's role in platelet biology and suggests that targeting PGE2 pathways could lead to personalized antiplatelet therapy without affecting hemostasis, but it presents no new results.

This article discusses the pursuit of more effective treatments for androgenetic alopecia due to its widespread psychological and social impact, but reports no new clinical findings.

This review discusses the potential roles of prostaglandin D2 and its receptor CRTH2 in various diseases beyond allergies and asthma and reports no new clinical results.

This review discusses the role of LPA(3) in embryo implantation and its genetic connection with prostaglandin signaling, but reports no new clinical results.

This study found that dihydrotestosterone (DHT) suppresses prostaglandin E2 and TGF-β induced IGF-I gene promoter activity in osteoblasts, suggesting complex interactions among bone growth regulators and potential complications from anabolic steroid use.

This review suggests that imbalance in prostaglandin levels may contribute to androgenetic alopecia, highlighting prostaglandins as potential biomarkers and therapeutic targets for the condition.

This study found that prostaglandin receptors are widely expressed in hair follicles, suggesting a complex network of prostanoid pathways involved in hair growth control.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

This review synthesizes current knowledge on eyelash hair follicles, highlighting gaps in understanding their biology and proposing future research directions; it reports no new experimental findings.

This study suggests that setipiprant's inhibitory effect on aldose reductase may contribute to its anti-inflammatory properties, adding a possible mechanism beyond its known action on the prostaglandin D2 receptor.

This article discusses the clinical spectrum and pathobiology of radiotherapy-induced alopecia and reports no new research findings, highlighting potential pathways for future targeted RIA management.

This study provides a comprehensive platform to explore stem cell interactions regulating hair follicle growth, revealing key signaling pathways in epithelial-mesenchymal interactions using advanced RNA sequencing and transgenic reporters.

New app improves storm surge predictions; advances in baldness treatment show potential but require time.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

In this study, low-dose BPA was associated with induced prostatic hyperplasia in rats, potentially mediated by COX-2 and L-PGDS through pathways involving cell proliferation and apoptosis.

This review by St. Denis et al. highlights that prostaglandin E2 is overexpressed in several skin cancers and suggests targeting its pathway could offer potential treatments for these malignancies.

Prostaglandin D2, found in higher levels in bald scalps, stops hair growth and could be a target for treating hair loss.

Blocking a compound called prostaglandin D₂ might help treat hair loss.

This case study describes a 16-year-old girl with alopecia areata affecting her eyelashes and eyebrows, who showed very limited response to treatment with topical mometasone furoate and subsequent partial hair loss upon stopping the treatment.